Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
SEATTLE, Jan. 27, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City.
Brad Gray, President and Chief Executive Officer, is scheduled to present on Wednesday, February 10, 2016 at 1:50pm ET. Interested parties can access the live webcast from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
